South Dakota's attorney general has told state lawmakers that the state's medical marijuana program needs no overhaul following the federal reclassification of cannabis as a Schedule 3 substance. The opinion, delivered to a legislative oversight committee this month, lands at a moment when operators nationwide are anxiously trying to figure out whether rescheduling drags state-licensed cannabis businesses into the FDA's regulatory machinery. For now, at least in South Dakota, the answer is no.
What the opinion actually settles
Attorney General Marty Jackley's analysis addresses a question that has been circulating in compliance departments and law firms since the Drug Enforcement Administration's April move: does Schedule 3 status mean state medical cannabis programs now conflict with federal law? Jackley concluded there's no preemption problem. Congress hasn't expressly blocked state action, hasn't claimed exclusive authority over marijuana regulation, and South Dakota's statute doesn't clash with the new federal schedule. That's a fairly clean legal finding, and it matters because preemption fears have been quietly driving some of the more alarmist talk in the industry.
The opinion also tackles the FDA question directly. Other Schedule 3 drugs typically require a prescription and FDA approval through clinical trials, plus adherence to good manufacturing practice standards. Some attorneys have warned that this same framework could eventually apply to state-licensed cannabis products - meaning dispensaries selling flower, vapes, or edibles without FDA sign-off could suddenly find themselves out of compliance. Jackley's memo pushes back on that read, at least in the near term, noting that current federal rules permit state medical marijuana programs to keep functioning as long as operators hold proper state licensing and register with the DEA.
Why this matters beyond South Dakota's borders
South Dakota isn't a major cannabis market by revenue, but the legal reasoning here is portable. Other states with legislative committees, attorneys general, or industry associations asking the same preemption and FDA questions now have a model opinion to reference. For multi-state operators juggling compliance logs across a dozen different regulatory regimes, that's not nothing - a consistent legal theory adopted across several states reduces the odds of a messy, state-by-state patchwork response to rescheduling.
There's a political backstory worth noting too. A bill introduced last year in South Dakota would have automatically repealed the state's MMJ law the moment federal rescheduling took effect - a kind of built-in sunset clause driven by skepticism toward the state's cannabis program. That bill died, and its two lead sponsors lost their Republican primary races over the summer. Whether voters were responding to cannabis policy specifically or broader political currents is impossible to say, but the legislative appetite for unwinding medical marijuana access in the state has clearly cooled.
The bigger rescheduling picture remains unresolved
None of this touches the separate, much larger fight over whether all cannabis - including adult-use product, not just medical - gets reclassified under federal law. That proceeding sits before a DEA administrative law judge and remains stalled while opponents push the Department of Justice to weigh a Government Accountability Office report criticizing the process used to determine cannabis has accepted medical use. Additional briefings are expected later this month, and the stall has mostly killed hope of a resolution before the midterm elections.
For operators, the practical takeaway is narrower but still useful: the Schedule 3 move hasn't yet triggered the feared cascade of FDA-style compliance burdens for state-licensed medical cannabis businesses, at least according to this reading of federal law. The 280E tax relief question - and whether any retroactive relief might offset outstanding tax liability tied to the old Schedule 1 treatment - remains a separate and still-unresolved issue working through its own channels. Operators would do well to keep watching both tracks rather than assuming one resolves the other.